HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Do NAD Decisions Serve As Class Action Fodder?

This article was originally published in The Rose Sheet

Executive Summary

“Piggyback” lawsuits following National Advertising Division decisions have raised concerns among firms participating in NAD’s self-regulatory process. Attorneys discuss at the NAD Annual Conference Oct. 1 in New York.

You may also be interested in...



NAD Participation Poses Minimal Class-Action Risk – Attorney Analysis

An investigation led by attorney John Villafranco, a partner with Kelley Drye & Warren, suggests that the risk of incurring a consumer class-action lawsuit as a result of participating in NAD’s self-regulatory process is “much lower than many have assumed it to be.”

Prop 65 Litigators Turning Sights On Beauty Industry, Lawyer Says

Prop 65 suits tend to hit industries in waves, and there are indications that the beauty industry is next, says Angela Diesch, attorney for Sacrament, Calif.-based Greenberg Traurig. Marketers of products containing methyl eugenol, lead or cocamide DEA should ensure they are complying with the California law.

NAD: Firms Should Be Forthcoming, Focused When Undergoing Reviews

Attorneys from the National Advertising Division offer advice for advertisers and challengers participating in the industry’s self-regulatory review process.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel